U.S. Markets open in 2 hrs 51 mins

Spectrum Pharmaceuticals, Inc. (SPPI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.5500+0.0200 (+1.31%)
At close: 04:00PM EST
1.5400 -0.01 (-0.65%)
After hours: 07:53PM EST

Spectrum Pharmaceuticals, Inc.

11500 South Eastern Avenue
Suite 240
Henderson, NV 89052
United States
702 835 6300

Full Time Employees175

Key Executives

NameTitlePayExercisedYear Born
Mr. Joseph W. TurgeonPres, CEO & Director1.42MN/A1958
Mr. Kurt A. GustafsonExec. VP & CFO953.39kN/A1968
Mr. Thomas J. RigaExec. VP, COO & Chief Commercial Officer1.03MN/A1976
Mr. Keith M. McGahan J.D., L.L.M.Exec. VP, Chief Legal Officer & Corp. Sec.842.19kN/A1976
Dr. Francois J. Lebel FRCPC, M.D.Exec. VP & Chief Medical Officer926.76kN/A1952
Mr. Shivpreet KapoorVP of Strategic Planning & Investor RelationsN/AN/AN/A
Mr. Bimal R. ShahVP of Corp. & Bus. Devel.N/AN/AN/A
Mr. Alberto DejesusVP of MarketingN/AN/AN/A
Ms. Lisa A. CroissantVP of SalesN/AN/AN/A
Dr. Zane Yang M.D.Sr. VP of Clinical Devel.N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include ROLONTIS, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Henderson, Nevada.

Corporate Governance

Spectrum Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 1; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.